Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249610 | 0.89 | SIGMAR1 (0.70) | SIGMAR1POLBHRH3ALDH1A1KMT2A | |
| SCHEMBL23235098 | 0.85 | SIGMAR1 (0.60) | SIGMAR1POLBL3MBTL3HRH3MBTD1 | |
| SCHEMBL28626129 | 0.82 | HRH3 (0.68) | SIGMAR1L3MBTL3HRH3MBTD1L3MBTL1 | |
| SCHEMBL5253680 | 0.81 | SIGMAR1 (0.60) | SIGMAR1POLBL3MBTL3HRH3MBTD1 | |
| SCHEMBL22711455 | 0.81 | SIGMAR1 (0.60) | SIGMAR1POLBL3MBTL3HRH3MBTD1 | |
| SCHEMBL321095 | 0.81 | SIGMAR1 (0.60) | SIGMAR1POLBL3MBTL3HRH3MBTD1 | |
| SCHEMBL24022514 | 0.81 | SIGMAR1 (0.60) | SIGMAR1POLBL3MBTL3HRH3MBTD1 | |
| SCHEMBL25042302 | 0.81 | SIGMAR1 (0.65) | SIGMAR1POLBL3MBTL3HRH3MBTD1 | |
| SCHEMBL24351544 | 0.81 | SIGMAR1 (0.70) | SIGMAR1POLBL3MBTL3HRH3MBTD1 | |
| SCHEMBL23146342 | 0.81 | SIGMAR1 (0.60) | SIGMAR1POLBL3MBTL3HRH3MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336642-A1 | INHIBITORS OF 12/15-LIPOXYGENASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-10-10 | — | — | US | disclosed |
| CN-118382435-A | 12/15-Lipoxygenase inhibitors | 总医院公司 | 2024-07-23 | — | — | CN | disclosed |
| EP-4384161-A1 | INHIBITORS OF 12/15-LIPOXYGENASE | The General Hospital Corporation (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-111655685-B | Thiophene derivative and use thereof | 藤本株式会社 | 2023-11-17 | — | — | CN | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3744719-B1 | THIOPHENE DERIVATIVE AND USE THEREOF | FUJIMOTO CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023019090-A1 | INHIBITORS OF 12/15-LIPOXYGENASE | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023019090-A1 | INHIBITORS OF 12/15-LIPOXYGENASE | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-20160159768-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-9309219-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150224104-A1 | METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER | CELGENE CORPORATION | 2015-08-13 | — | — | US | disclosed |
| EP-2892537-A1 | METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER | Celgene Corporation (US) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014039960-A1 | METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER | CELGENE CORPORATION (US) | 2014-03-13 | — | — | WO | disclosed |
| US-20130324518-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2536706-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011100380-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336642-A1 | INHIBITORS OF 12/15-LIPOXYGENASE | ALOX15, LOX, ALOX12 | SIGMAR1 2740/4885POLB 2835/4885L3MBTL3 2869/4885 |
| US-20130324518-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | SIGMAR1 264/4885POLB 1756/4885L3MBTL3 3616/4885 |
| US-20160159768-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | SIGMAR1 264/4885POLB 1756/4885L3MBTL3 3616/4885 |
| US-20150224104-A1 | METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER | BRCA1, TP53, CCR3 | SIGMAR1 1733/4885POLB 2186/4885L3MBTL3 475/4885 |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP3A4, CYP3A43 | SIGMAR1 264/4885POLB 1756/4885L3MBTL3 3616/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | SIGMAR1 264/4885POLB 1756/4885L3MBTL3 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.